TL;DR
This paper presents a novel automatic temperature compensation system designed to precisely control the temperature of heated chemotherapy drugs during HIPEC surgery. By employing a smart heat comparison/judgment algorithm and a look-up table (LUT), the system ensures the drug remains within the critical 41-43°C range, enhancing treatment efficacy and minimizing damage to healthy tissues.
What Problem Does This Paper Address?
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) surgery is a crucial treatment for residual tumors after surgeries for cancers like ovarian and colorectal cancer. It involves injecting heated chemotherapy drugs into the abdominal cavity to destroy cancer cells. However, maintaining the precise temperature of these drugs (ideally between 41°C and 43°C) is challenging. As the drug circulates, its temperature can drop, reducing therapeutic effectiveness, or rise too high, potentially damaging normal tissues. Current methods rely on manual temperature control, which is cumbersome, time-consuming, and prone to human error. This paper addresses the need for an automated, precise, and reliable system to maintain the optimal drug temperature during HIPEC surgery.
Methods
The core of the proposed system is a Smart Heat Comparison/Judgment and Control mechanism. It utilizes a temperature comparator (TC) to compare the actual drug temperature ($T_o$) with a reference temperature ($T_{ref}$, set between 41-43°C). This comparison generates a temperature difference signal ($T_{dif}$). This signal is then fed into a Look-Up Table (LUT), which acts as a decision-making module. Based on the $T_{dif}$ value, the LUT outputs a command signal to a heat exchanger.
The LUT has four primary commands:
- $T_p$ (Heat Up): If $T_{dif}$ indicates the temperature is below 41°C, the heat exchanger is instructed to increase the drug temperature.
- $T_s$ (Hold): If the temperature is within the 41-43°C range, the system maintains the current state.
- $T_a$ (Cool Down): If $T_{dif}$ indicates the temperature is above 44°C, the heat exchanger is instructed to reduce the drug temperature.
- $T_x$ (Stop): If the temperature exceeds 46°C, the system is halted to prevent damage.
The system also incorporates a temperature-to-voltage converter (TVC) and an analog-to-digital converter (ADC) to process sensor readings and generate digital signals for the TC and LUT. The paper emphasizes the importance of a fast response signal for accurate comparison and judgment, reporting a response time of 0.209 µs.
Datasets
Not discussed in the paper. The study focuses on experimental validation using a simulated HIPEC environment (beaker with saline) and thermal imaging.
Key Insights and Ideas
- The critical temperature window: Maintaining the drug temperature between 41-43°C is paramount for effective cancer cell destruction while minimizing harm to healthy tissues. Deviations outside this narrow range significantly impact treatment outcomes.
- LUT as a smart decision-maker: The LUT is the brain of the system, translating temperature differences into precise control commands for the heat exchanger. Its design is crucial for the system's responsiveness and accuracy.
- Speed is of the essence: The paper highlights that a faster response time in temperature comparison and judgment directly correlates with reduced operational errors and improved system reliability. The achieved response time of 0.209 µs is a key performance indicator.
- Automated control for safety and efficiency: Automating the temperature control process eliminates the need for manual intervention, reducing the risk of human error and freeing up medical staff. This leads to a more efficient and safer surgical procedure.
Key Results
- The proposed system demonstrated the ability to accurately maintain the drug temperature within the desired 41-43°C range.
- The system achieved a high response speed, with a response time of 0.209 µs.
- The accuracy, reliability, and reproducibility of the module's operation were reported to be 98.2%.
- The error for the delay time of the module was within 1.8%.
- Experimental results, including thermal imaging, confirmed that the system effectively controlled the temperature of the simulated peritoneal fluid.
Limitations and Future Work
- Animal experiments: The authors acknowledge that while their experiments were conducted in a simulated environment, animal experiments are necessary for future commercialization.
- Clinical trials: The study was not a clinical trial, and further validation in actual HIPEC surgeries is required.
- Commercialization: The proposed system has good application prospects and could be applied to surgery, obstetrics, and gynecology, but further development and testing are needed for widespread adoption.
Summary updated